{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:57:16Z","timestamp":1777100236507,"version":"3.51.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/jac\/dkx448","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T20:14:13Z","timestamp":1512418453000},"page":"i44-i50","source":"Crossref","is-referenced-by-count":41,"title":["We can do better: a fresh look at echinocandin dosing"],"prefix":"10.1093","volume":"73","author":[{"given":"Justin C","family":"Bader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata M","family":"Bhavnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Andes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"key\n\t\t\t\t20180111045241_dkx448-B1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.34.2.183","article-title":"Amphotericin B: current understanding of mechanisms of action","volume":"34","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2133.1999.00011.x","article-title":"Drug interactions of the newer oral antifungal agents","volume":"141","year":"1999","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B3","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/13543784.12.8.1313","article-title":"The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy","volume":"12","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B4","author":"United States Food and Drug Administration"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B5","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s10096-014-2096-9","article-title":"Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?","volume":"33","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B6","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1128\/AAC.01005-15","article-title":"Rapid development of Candida krusei echinocandin resistance during caspofungin therapy","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jac\/dkp444","article-title":"Caspofungin-non-susceptible Candida isolates in cancer patients","volume":"65","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B8","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/JCM.02390-09","article-title":"Breakthrough invasive candidiasis in patients on micafungin","volume":"48","year":"2010","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B9","first-page":"e01229","article-title":"Echinocandin resistance in Candida species isolates from liver transplant recipients","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/tid.12230","article-title":"Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy","volume":"16","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/JCM.02120-10","article-title":"Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin","volume":"49","year":"2011","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijantimicag.2009.09.020","article-title":"Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review","volume":"35","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B13","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1128\/AAC.00836-10","article-title":"FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s40588-015-0015-1","article-title":"Update on antifungal drug resistance","volume":"2","year":"2015","journal-title":"Curr Clin Microbiol Rep"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B16","first-page":"1833","article-title":"Drug-resistant Candida glabrata infection in cancer patients","volume":"20","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","article-title":"Pharmacokinetics and pharmacodynamics of antifungals","volume":"20","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"52","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B20"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B21","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1093\/cid\/cis001","article-title":"In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans","volume":"54","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B22","author":"The Medicines Company","year":"2016"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B23","first-page":"38","article-title":"Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections","volume":"9","year":"1997","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B24","first-page":"S12","article-title":"The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy","volume":"95","year":"2001","journal-title":"Respir Med"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B25","year":"2017"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B26","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"Comparison of the efficacy and safety of oritavancin in front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B27","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B29","doi-asserted-by":"crossref","first-page":"R1121","DOI":"10.1016\/j.cub.2008.09.039","article-title":"The evolution of haploidy and diploidy","volume":"18","year":"2008","journal-title":"Curr Biol"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"39","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/598933","article-title":"A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis","volume":"48","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B33"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B34","first-page":"e00906","article-title":"Monitoring antifungal resistance in a global collection of invasive yeasts and moulds: application of CLSI epidemiological cutoff values and whole genome sequencing analysis for detection of azole resistance in Candida albicans","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B35","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B38","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jac\/dkq081","article-title":"Echinocandin pharmacodynamics: review and clinical implications","volume":"65","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B39","author":"Pfizer Inc.","year":"2016"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B40","author":"Merck Sharpe & Dohme Corp","year":"2017"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B41","author":"Astellas Pharma US, Inc.","year":"2016"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/AAC.01337-06","article-title":"Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia","volume":"51","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B43","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.02124-15","article-title":"Efficacy of extended-interval dosing of micafungin evaluated using a pharmacokinetic\/pharmacodynamic study with humanized doses in mice","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B44","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B45"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B46","first-page":"e01627","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B47"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B48","first-page":"e02045","article-title":"Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 antifungal surveillance program","volume":"61","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B49","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.49.4.1331-1336.2005","article-title":"Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant","volume":"49","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B51","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.05193-11","article-title":"Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180111045241_dkx448-B52","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jac\/dku477","article-title":"A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/suppl_1\/i44\/23415614\/dkx448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T22:09:36Z","timestamp":1660082976000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/73\/suppl_1\/i44\/4769706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":52,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2018,1,3]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx448","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1,1]]}}}